Your Cosmetic Formulations Contain PFAS. The FDA Has Noticed. Have You?

For years, PFAS in cosmetics was a background concern — something discussed in environmental circles, flagged occasionally by advocacy groups, but rarely treated as an urgent business issue by manufacturers. That era is over.

The FDA has completed a structured review of intentionally added PFAS in cosmetic formulations. The findings are specific, the regulatory implications are concrete, and the window for getting ahead of this is closing.

First, a Distinction That Changes Everything

Not all PFAS exposure is equal in the eyes of regulators — and understanding why is the foundation of everything that follows.

PFAS that enter products as trace contaminants — through raw materials, processing equipment, or packaging — are one category of concern. But intentionally added PFAS are in an entirely different regulatory position. These are substances a formulator deliberately selects because of what they do: repel water and oil, extend wear, improve texture, enhance durability. They are not incidental. They are ingredients — and that makes the manufacturer directly and unambiguously responsible for them.

The FDA's review confirmed that this practice is far from niche. 51 PFAS were identified as intentionally added ingredients across 1,744 cosmetic and personal care formulations currently on the U.S. market. If you manufacture cosmetics, the probability that this touches your portfolio is high.

The FDA's Findings, Plainly Stated

Focusing on the 25 most prevalent PFAS ingredients in cosmetics, the FDA evaluated available toxicological data and reached conclusions that every formulator and regulatory team should understand:

Five ingredients present lower safety concern under typical conditions of use — PTFE, Perfluorodecalin, HC Yellow No. 13, Perfluorohexane, and Tetrafluoropropene. These occupy the clearest ground today, though "lower concern" is not a permanent designation in a rapidly evolving regulatory environment.

One ingredient is flagged as a potential concern — Perfluorohexylethyl Triethoxysilane, specifically at higher concentrations in leave-on products like body lotion. If this appears anywhere in your formulations, it requires active management, not periodic check-ins.

Nineteen ingredients sit in the insufficient data category — including Perfluorononyl Dimethicone and Trifluoroacetyl Tripeptide-2. This is the number that should give manufacturers pause. Nearly four out of every five PFAS reviewed could not be conclusively assessed because the science simply isn't there yet.

Here is what that means in practice: regulators are not waiting for complete data before acting. In jurisdiction after jurisdiction, insufficient evidence is being treated as a reason for precaution — not a reason for patience.

The Legislation Isn't Coming. It's Here.

Some manufacturers are still treating PFAS compliance as a future problem — something to address when federal standards solidify or when their specific product category gets targeted. That approach is already out of date.

Minnesota, Maine, New Mexico, Washington, and Connecticut have enacted reporting and notification requirements for intentionally added PFAS. These are not proposals or pilot programs. They are active laws with real obligations attached to them — obligations that differ by state, apply to different product categories on different timelines, and carry consequences for non-compliance.

The pipeline is full. More states are advancing similar legislation. International markets are moving in parallel. Every month that passes without a structured compliance response is a month of accumulating regulatory exposure.

The Standard Has Changed — Has Your Program?

What regulators now expect from cosmetic manufacturers goes well beyond listing ingredients on a label. The emerging standard is formulation accountability: the ability to identify every intentionally added PFAS in your product portfolio, demonstrate awareness of its regulatory status in every market where you sell, and show that you are actively managing the associated obligations.

That is a materially higher bar than most compliance programs were built to meet. Closing the gap requires four things:

Complete portfolio visibility. You cannot manage what you have not mapped. Every product, every formulation, every intentionally added PFAS — identified, documented, and current.

Jurisdiction-by-jurisdiction regulatory mapping. State requirements are not uniform. A reporting trigger in Maine is not the same as one in Washington. Managing this requires active tracking, not annual reviews.

Documentation built for scrutiny. As regulatory inquiries become more common, the ability to demonstrate what is in your products and why will be as important as the formulations themselves. Build that record now.

Reformulation strategy where it matters. For ingredients in the flagged or data-gap categories, the strategic question is not whether reformulation may eventually be necessary — it is whether you are evaluating it proactively or waiting until a regulatory deadline removes your options.

This Is the Signal. Don't Wait for the Alarm.

Regulatory patterns in the cosmetics industry are consistent. Agency attention becomes guidance. Guidance becomes requirements. Requirements become enforcement. The FDA's PFAS findings and the wave of state legislation that has followed represent the attention and guidance phase. Requirements and enforcement are what come next.

The manufacturers best positioned for what follows are not those with the fastest reaction time when new rules publish. They are the ones who read the direction of travel early, built their compliance infrastructure before it was mandated, and turned a regulatory challenge into a competitive differentiator.

Intentional use is intentional responsibility. The only real question is whether your organization is prepared to own it.